open access

Vol 84, No 10 (2013)
ARTICLES
Get Citation

Evaluation of the usefulness of endoglin level as a predictor of preeclampsia in pregnant women with hypertension

Monika Głuchowska, Urszula Kowalska-Koprek, Agata Karowicz-Bilińska
DOI: 10.17772/gp/1648
·
Ginekol Pol 2013;84(10).

open access

Vol 84, No 10 (2013)
ARTICLES

Abstract

Introduction: Preeclampsia is a pregnancy-specific syndrome that occurs after the 20 weeks of pregnancy, and is characterized by hypertension and proteinuria. It complicates approximately 5-6% of all pregnancies and is a major factor in fetal and neonatal mortality. Objectives: The aim of this study was to evaluate serum concentration of soluble endoglin (sEng) as the predictorn of preeclampsia in pregnant women with hypertension. Material and methods: The study was conducted at the Department of Pathology of Pregnancy (Department of Gynecology and Obstetrics, Medical University of Lodz), and the clinical ambulatory of the WSSz – M. Madurowicz (at present, WSSz – M. Pirogow) in Lodz, between 2008-2012. The Committee of Bioethics, Medical University of Lodz approved of the research (RNN/106/08/KE, May 20, 2008). The study included 86 pregnant women, between 25 and 40 weeks of pregnancy. The subjects were divided into 3 groups: – Group HA – 33 pregnant women with hypertension arterialis (≥140/90 mmHg) without proteinuria, – Group P – 21 pregnant women with hypertension arterialis (≥140/90 mmHg) with proteinuria, – Group K – 32 pregnant women with normal blood pressure (<140/90 mmHg) without proteinuria. Markings were determined with the ELISA method, using Quantikine kit. Results: A significantly higher value of endoglin levels were found in pregnant women with preeclampsia syndrome (P) than in women with hypertension (HA) and the control group (K). Levels of endoglin in the P group was 29.70 pg/ml, 19.54 pg/ml in the HA group and 12.99 pg/ml in the K group. Conclusions: Elevated serum concentration of soluble endoglin (SENG) in pregnant women constitutes a risk factor for preeclampsia.

Abstract

Introduction: Preeclampsia is a pregnancy-specific syndrome that occurs after the 20 weeks of pregnancy, and is characterized by hypertension and proteinuria. It complicates approximately 5-6% of all pregnancies and is a major factor in fetal and neonatal mortality. Objectives: The aim of this study was to evaluate serum concentration of soluble endoglin (sEng) as the predictorn of preeclampsia in pregnant women with hypertension. Material and methods: The study was conducted at the Department of Pathology of Pregnancy (Department of Gynecology and Obstetrics, Medical University of Lodz), and the clinical ambulatory of the WSSz – M. Madurowicz (at present, WSSz – M. Pirogow) in Lodz, between 2008-2012. The Committee of Bioethics, Medical University of Lodz approved of the research (RNN/106/08/KE, May 20, 2008). The study included 86 pregnant women, between 25 and 40 weeks of pregnancy. The subjects were divided into 3 groups: – Group HA – 33 pregnant women with hypertension arterialis (≥140/90 mmHg) without proteinuria, – Group P – 21 pregnant women with hypertension arterialis (≥140/90 mmHg) with proteinuria, – Group K – 32 pregnant women with normal blood pressure (<140/90 mmHg) without proteinuria. Markings were determined with the ELISA method, using Quantikine kit. Results: A significantly higher value of endoglin levels were found in pregnant women with preeclampsia syndrome (P) than in women with hypertension (HA) and the control group (K). Levels of endoglin in the P group was 29.70 pg/ml, 19.54 pg/ml in the HA group and 12.99 pg/ml in the K group. Conclusions: Elevated serum concentration of soluble endoglin (SENG) in pregnant women constitutes a risk factor for preeclampsia.
Get Citation

Keywords

preeclampsia, soluble andoglin, pregnancy, arterial hypertension

About this article
Title

Evaluation of the usefulness of endoglin level as a predictor of preeclampsia in pregnant women with hypertension

Journal

Ginekologia Polska

Issue

Vol 84, No 10 (2013)

DOI

10.17772/gp/1648

Bibliographic record

Ginekol Pol 2013;84(10).

Keywords

preeclampsia
soluble andoglin
pregnancy
arterial hypertension

Authors

Monika Głuchowska
Urszula Kowalska-Koprek
Agata Karowicz-Bilińska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl